Structure-antifungal activity relationships of polyene antibiotics of the amphotericin B group. 2013

Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
Gause Institute of New Antibiotics, Moscow, Russia.

A comprehensive comparative analysis of the structure-antifungal activity relationships for the series of biosynthetically engineered nystatin analogues and their novel semisynthetic derivatives, as well as amphotericin B (AMB) and its semisynthetic derivatives, was performed. The data obtained revealed the significant influence of the structure of the C-7 to C-10 polyol region on the antifungal activity of these polyene antibiotics. Comparison of positions of hydroxyl groups in the antibiotics and in vitro antifungal activity data showed that the most active are the compounds in which hydroxyl groups are in positions C-8 and C-9 or positions C-7 and C-10. Antibiotics with OH groups at both C-7 and C-9 had the lowest activity. The replacement of the C-16 carboxyl with methyl group did not significantly affect the in vitro antifungal activity of antibiotics without modifications at the amino group of mycosamine. In contrast, the activity of the N-modified derivatives was modulated both by the presence of CH3 or COOH group in the position C-16 and by the structure of the modifying substituent. The most active compounds were tested in vivo to determine the maximum tolerated doses and antifungal activity on the model of candidosis sepsis in leukopenic mice (cyclophosphamide-induced). Study of our library of semisynthetic polyene antibiotics led to the discovery of compounds, namely, N-(L-lysyl)-BSG005 (compound 3n) and, especially, L-glutamate of 2-(N,N-dimethylamino)ethyl amide of S44HP (compound 2j), with high antifungal activity that were comparable in in vitro and in vivo tests to AMB and that have better toxicological properties.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D009761 Nystatin Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3. Fungicidin,Mycostatin,Nilstat,Nystatin A1,Nystatin A2,Nystatin A3,Nystatin G,Stamicin,Stamycin
D011090 Polyenes Hydrocarbons with more than one double bond. They are a reduced form of POLYYNES. Cumulenes
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug

Related Publications

Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
April 1961, Antibiotics & chemotherapy (Northfield, Ill.),
Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
May 1977, The Analyst,
Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
January 1966, Antimicrobial agents and chemotherapy,
Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
August 1982, The Journal of infectious diseases,
Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
September 1965, The Indian journal of medical research,
Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
August 1963, The Journal of pharmacy and pharmacology,
Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
January 2005, Acta biochimica Polonica,
Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
November 1960, Hindustan antibiotics bulletin,
Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
January 1963, Fortschritte der Chemie organischer Naturstoffe = Progress in the chemistry of organic natural products. Progres dans la chimie des substances organiques naturelles,
Anna N Tevyashova, and Evgenia N Olsufyeva, and Svetlana E Solovieva, and Svetlana S Printsevskaya, and Marina I Reznikova, and Aleksei S Trenin, and Olga A Galatenko, and Ivan D Treshalin, and Eleonora R Pereverzeva, and Elena P Mirchink, and Elena B Isakova, and Sergey B Zotchev, and Maria N Preobrazhenskaya
January 1984, Biochemical pharmacology,
Copied contents to your clipboard!